> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Recommends More Leqembi MRIs
- URL: https://www.fdaweb.com/fda-recommends-more-leqembi-mris/
- Published: 2025-08-28T12:00:00.000Z
- Updated: 2026-09-14T15:20:22.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5159778

FDA is recommending an additional, earlier MRI monitoring scan before the third infusion of Eisai/Biogen’s Leqembi (lecanemab) for Alzheimer’s disease patients. An agency [statement](https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommend-additional-earlier-mri-monitoring-patients-alzheimers-disease-taking-leqembi-lecanemab?utm%5Fmedium=email&utm%5Fsource=govdelivery) says the earlier monitoring “can identify individuals with amyloid-related imaging abnormalities with edema (ARIA-E), which is characterized by brain swelling or fluid build-up.”

The notice says that identifying patients with ARIA-E can lead healthcare professionals, patients, and their families to delay or discontinue Leqembi treatment to potentially mitigate the serious and sometimes fatal events.

FDA says the Leqembi labeling will be changed to include the earlier monitoring between the second and third infusion.